JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Journal of Experimental & Clinical Cancer Research (JECCR) is the official scientific journal of the “Regina Elena” National Cancer Institute since 1986 which publishes manuscripts regarding significant advances in basic cancer research and offers a translational bridge from the laboratory to the clinic.

The most important aims are to open new roads for the understanding, prevention, diagnosis and treatment of cancer and to share the scientific results with the international scientific community.

JECCR has led its editorial activity by maintaining its partnership with the publisher BioMed Central - Springer Nature in London.

Thanks to its “open access” version, JECCR improved its performance in terms of rapid publication of the articles, better widespread all scientific results and higher visibility in the scientific community confirming its position in the 1st quartile among International Oncology Journals

In 2020 JECCR has launched a new Special Issue regarding the latest highlights on the role of hypoxia in all aspects of tumor progression, including therapy resistance and metastases in light of the 2019 Nobel Prize in Medicine.

The main accomplishments achieved by JECCR in 2020 are:

  • Impact Factor 7.068;
  • 1570578 downloads;
  • 2861 submissions;
  • 271 accepted papers;
  • 257 published papers;

Most of submitted and published articles in the last years comes from International Oncology Institutes and Universities worldwide.

Moreover in this year, the “Journal of Experimental & Clinical Cancer Research” has reinforced its visibility in the international scientific community sharing the latest articles and collections by Social Media.

JECCR online website

Top 5 JECCR publication most cited in 2020

1. Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis

By: Huang, Xiu-Yan; Huang, Zi-Li; Huang, Jin; et al.
Volume: 39 Issue: 1 Article Number: 20 Published: JAN 23 2020 Times Cited: 27

2. Circular RNA circRHOBTB3 acts as a sponge for miR-654-3p inhibiting gastric cancer growth

By: Deng, Guangxu; Mou, Tingyu; He, Jiayong; et al.
Volume: 39 Issue: 1 Article Number: 1Published: JAN 13 2020 Times Cited: 26

3. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway

By: Lou, Guohua; Chen, Liang; Xia, Caixia; et al.
Volume: 39 Issue: 1 Article Number: 4 Published: JAN 2 2020 Times Cited: 16

4. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells

By: Masoumi, Elham; Jafarzadeh, Leila; Mirzaei, Hamid Reza; et al.
Volume: 39 Issue: 1 Article Number: 49 Published: MAR 10 2020 Times Cited: 14

5. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways

By: Yoshida, Go J.
Volume: 39 Issue: 1 Article Number: 112 Published: JUN 16 2020 Times Cited: 13

 

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Journal of Experimental & Clinical Cancer Research (JECCR) is the official scientific journal of the “Regina Elena” National Cancer Institute since 1986 which publishes manuscripts regarding significant advances in basic cancer research and offers a translational bridge from the laboratory to the clinic.

The most important aims are to open new roads for the understanding, prevention, diagnosis and treatment of cancer and to share the scientific results with the international scientific community.

JECCR has led its editorial activity by maintaining its partnership with the publisher BioMed Central - Springer Nature in London.

Thanks to its “open access” version, JECCR improved its performance in terms of rapid publication of the articles, better widespread all scientific results and higher visibility in the scientific community confirming its position in the 1st quartile among International Oncology Journals

In 2020 JECCR has launched a new Special Issue regarding the latest highlights on the role of hypoxia in all aspects of tumor progression, including therapy resistance and metastases in light of the 2019 Nobel Prize in Medicine.

The main accomplishments achieved by JECCR in 2020 are:

  • Impact Factor 7.068;
  • 1570578 downloads;
  • 2861 submissions;
  • 271 accepted papers;
  • 257 published papers;

Most of submitted and published articles in the last years comes from International Oncology Institutes and Universities worldwide.

Moreover in this year, the “Journal of Experimental & Clinical Cancer Research” has reinforced its visibility in the international scientific community sharing the latest articles and collections by Social Media.

JECCR online website

Top 5 JECCR publication most cited in 2020

1. Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis

By: Huang, Xiu-Yan; Huang, Zi-Li; Huang, Jin; et al.
Volume: 39 Issue: 1 Article Number: 20 Published: JAN 23 2020 Times Cited: 27

2. Circular RNA circRHOBTB3 acts as a sponge for miR-654-3p inhibiting gastric cancer growth

By: Deng, Guangxu; Mou, Tingyu; He, Jiayong; et al.
Volume: 39 Issue: 1 Article Number: 1Published: JAN 13 2020 Times Cited: 26

3. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway

By: Lou, Guohua; Chen, Liang; Xia, Caixia; et al.
Volume: 39 Issue: 1 Article Number: 4 Published: JAN 2 2020 Times Cited: 16

4. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells

By: Masoumi, Elham; Jafarzadeh, Leila; Mirzaei, Hamid Reza; et al.
Volume: 39 Issue: 1 Article Number: 49 Published: MAR 10 2020 Times Cited: 14

5. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways

By: Yoshida, Go J.
Volume: 39 Issue: 1 Article Number: 112 Published: JUN 16 2020 Times Cited: 13